1
ChemInform 2009, 40, issue 14 © 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.cheminform.wiley-vch.de Antimicrobial activity X 0060 Design at the Atomic Level: Generation of Novel Hybrid Biaryloxazolidinones as Promising New Antibiotics. — The ribosomal selectivity of the title compounds is evaluated through inhibition of translation of ribosomes derived from both E. coli and rabbit reticulocyte. (I) and (IIa) are potent inhibitors of E. coli and are non-selective, whereas (IIIa) shows greater selectivity. (IIb) and (IIIb) are less potent against E. coli but demonstrate improved selectivity for bacterial ribosomes over those of rabbit re- ticulocyte. — (JOHNSON*, G.; et al.; Bioorg. Med. Chem. Lett. 18 (2008) 23, 6179-6183; Dep. Struct.-Based Drug Des., Rib-X Pharm. Inc., New Haven, CT 06511, USA; Eng.) — M. Bohle 14- 214

ChemInform Abstract: Design at the Atomic Level: Generation of Novel Hybrid Biaryloxazolidinones as Promising New Antibiotics

Embed Size (px)

Citation preview

Page 1: ChemInform Abstract: Design at the Atomic Level: Generation of Novel Hybrid Biaryloxazolidinones as Promising New Antibiotics

www.cheminform.wiley-vch.de

Antimicrobial activityX 0060 Design at the Atomic Level: Generation of Novel Hybrid Biaryloxazolidinones as

Promising New Antibiotics. — The ribosomal selectivity of the title compounds is evaluated through inhibition of translation of ribosomes derived from both E. coli and rabbit reticulocyte. (I) and (IIa) are potent inhibitors of E. coli and are non-selective, whereas (IIIa) shows greater selectivity. (IIb) and (IIIb) are less potent against E. coli but demonstrate improved selectivity for bacterial ribosomes over those of rabbit re-ticulocyte. — (JOHNSON*, G.; et al.; Bioorg. Med. Chem. Lett. 18 (2008) 23, 6179-6183; Dep. Struct.-Based Drug Des., Rib-X Pharm. Inc., New Haven, CT 06511, USA; Eng.) — M. Bohle

14- 214

ChemInform 2009, 40, issue 14 © 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim